mercaptopurine and Ileal-Diseases

mercaptopurine has been researched along with Ileal-Diseases* in 2 studies

Other Studies

2 other study(ies) available for mercaptopurine and Ileal-Diseases

Article	Year
Risk factors and outcome of acute severe lower gastrointestinal bleeding in Crohn's disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:9 Acute severe lower gastrointestinal bleeding in Crohn's disease is uncommon, but is a diagnostic and therapeutic challenge. We aimed to identify risk factors for acute lower gastrointestinal bleeding in patients with Crohn's disease and assess the cumulative probability of rebleeding in relation to therapeutic modality.. We retrospectively reviewed the medical records of 70 Crohn's patients (4.0%) with acute severe lower gastrointestinal bleeding and compared these with matched 140 Crohn's patients without bleeding.. The cumulative probability of bleeding after diagnosis of Crohn's disease was 1.7%, 3.6%, 6.5%, and 10.3% after 1, 5, 10, and 20 years respectively. At presentation, the median haemoglobin concentration was 8.4g/dL (range, 4.7-11.6g/dL). Use of azathioprine/6-mercaptopurine decreased the risk of lower gastrointestinal bleeding (OR: 0.525, 95% CI: 0.304-0.906, p=0.021). Bleeding recurred in 29 patients (41.4%) after a median time of 3.2 months (range, 15 days-94.7 months). One out of eleven patients treated with infliximab rebled. The cumulative probability of rebleeding tended to be lower in patients treated with infliximab than in those receiving other treatments (p=0.076).. Azathioprine/6-mercaptopurine may reduce the risk of acute severe lower gastrointestinal bleeding. The rebleeding is common, but infliximab may decrease rebleeding. Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Asian People; Azathioprine; Blood Transfusion; Case-Control Studies; Colonic Diseases; Crohn Disease; Embolization, Therapeutic; Female; Gastrointestinal Hemorrhage; Hemoglobins; Hemostasis, Endoscopic; Humans; Ileal Diseases; Immunosuppressive Agents; Infliximab; Kaplan-Meier Estimate; Male; Mercaptopurine; Middle Aged; Recurrence; Republic of Korea; Retrospective Studies; Risk Factors; Young Adult	2012
Splenic littoral cell hemangioendothelioma in a patient with Crohn's disease previously treated with immunomodulators and anti-TNF agents: a rare tumor linked to deep immunosuppression. The American journal of gastroenterology, 2011, Volume: 106, Issue:10 Topics: Azathioprine; Colonic Diseases; Crohn Disease; Gastrointestinal Agents; Hemangioendothelioma; Hemangioma; Humans; Ileal Diseases; Immunocompromised Host; Immunologic Factors; Immunosuppressive Agents; Male; Mercaptopurine; Middle Aged; Splenic Neoplasms; Tumor Necrosis Factor-alpha	2011

Article

Year

Risk factors and outcome of acute severe lower gastrointestinal bleeding in Crohn's disease.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:9

Acute severe lower gastrointestinal bleeding in Crohn's disease is uncommon, but is a diagnostic and therapeutic challenge. We aimed to identify risk factors for acute lower gastrointestinal bleeding in patients with Crohn's disease and assess the cumulative probability of rebleeding in relation to therapeutic modality.. We retrospectively reviewed the medical records of 70 Crohn's patients (4.0%) with acute severe lower gastrointestinal bleeding and compared these with matched 140 Crohn's patients without bleeding.. The cumulative probability of bleeding after diagnosis of Crohn's disease was 1.7%, 3.6%, 6.5%, and 10.3% after 1, 5, 10, and 20 years respectively. At presentation, the median haemoglobin concentration was 8.4g/dL (range, 4.7-11.6g/dL). Use of azathioprine/6-mercaptopurine decreased the risk of lower gastrointestinal bleeding (OR: 0.525, 95% CI: 0.304-0.906, p=0.021). Bleeding recurred in 29 patients (41.4%) after a median time of 3.2 months (range, 15 days-94.7 months). One out of eleven patients treated with infliximab rebled. The cumulative probability of rebleeding tended to be lower in patients treated with infliximab than in those receiving other treatments (p=0.076).. Azathioprine/6-mercaptopurine may reduce the risk of acute severe lower gastrointestinal bleeding. The rebleeding is common, but infliximab may decrease rebleeding.

Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Asian People; Azathioprine; Blood Transfusion; Case-Control Studies; Colonic Diseases; Crohn Disease; Embolization, Therapeutic; Female; Gastrointestinal Hemorrhage; Hemoglobins; Hemostasis, Endoscopic; Humans; Ileal Diseases; Immunosuppressive Agents; Infliximab; Kaplan-Meier Estimate; Male; Mercaptopurine; Middle Aged; Recurrence; Republic of Korea; Retrospective Studies; Risk Factors; Young Adult

2012

Splenic littoral cell hemangioendothelioma in a patient with Crohn's disease previously treated with immunomodulators and anti-TNF agents: a rare tumor linked to deep immunosuppression.

The American journal of gastroenterology, 2011, Volume: 106, Issue:10

Topics: Azathioprine; Colonic Diseases; Crohn Disease; Gastrointestinal Agents; Hemangioendothelioma; Hemangioma; Humans; Ileal Diseases; Immunocompromised Host; Immunologic Factors; Immunosuppressive Agents; Male; Mercaptopurine; Middle Aged; Splenic Neoplasms; Tumor Necrosis Factor-alpha

2011